Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/de-gruyter/post-powanie-u-pacjentek-z-nowotworem-mieloproliferacyjnym-bcr-abl-jPKqyrxC8n
- Publisher
- de Gruyter
- Copyright
- © 2019 Polish Society of Hematology and Transfusion Medicine, Insitute of Hematology and Transfusion Medicine. Published by Sciendo
- eISSN
- 2300-7117
- DOI
- 10.2478/ahp-2019-0023
- Publisher site
- See Article on Publisher Site
Abstract
StreszczenieCiąża u pacjentki z nowotworem mieloproliferacyjnym (myeloproliferative neoplasms – MPN) BCR-ABL ujemnym wiąże się z szeregiem możliwych powikłań dotyczących zarówno matki, jak i płodu, takich jak: częstsze powikłania zakrzepowe i krwotoczne u matki, zwiększone ryzyko poronień, częstsze dysfunkcje łożyska i związane z nimi: opóźnienie wzrostu płodu, porody przedwczesne, późne utraty płodu. Opieka nad ciężarną z MPN wymaga ścisłej współpracy specjalistów hematologa i ginekologa oraz wdrożenia postępowania zgodnego z obowiązującymi standardami (właściwej profilaktyki przeciwzakrzepowej i ewentualnego leczenia cytoredukcyjnego). W artykule omówiono aktualne zalecenia dotyczące monitorowania i terapii w trakcie ciąży i okresie połogu u kobiety z MPN.
Journal
Acta Haematologica Polonica – de Gruyter
Published: Sep 28, 2019
Recommended Articles
Loading...
References
-
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy
-
Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry
-
The management and outcome of 18 pregnancies in women with polycythemia vera
-
Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study
-
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia
-
The management and outcome of 18 pregnancies in women with polycythemia vera
-
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
-
Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms
-
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
-
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
-
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
-
Guidance for the treatment and prevention of obstetric-associated venous thromboembolism
-
Maternal age and fetal loss: population based register linkage study
-
Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies
-
Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis
-
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy
-
Myeloproliferative disorders in pregnancy
-
Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy
-
Guidance for the treatment and prevention of obstetric-associated venous thromboembolism
-
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia
-
Pregnancy and its management in the Philadelphia negative myeloproliferative diseases
-
Recurrent miscarriage: epidemiologic factors, definitions, and incidence
-
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia
-
Myeloproliferative disorders in pregnancy
-
NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
-
Recurrent miscarriage: epidemiologic factors, definitions, and incidence
-
Maternal age and fetal loss: population based register linkage study
-
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety
-
PARIS Collaborative Group. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data
-
Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety
-
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry
-
Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis
-
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis
-
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
-
Outcome of 121 pregnancies in patients with polycythemia vera (PV)
-
Management and outcomes of 27 pregnancies in women with myeloproliferative neoplasms
-
Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study
-
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
-
PARIS Collaborative Group. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data
-
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
-
Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy
-
Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies
-
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia
-
Outcome of 121 pregnancies in patients with polycythemia vera (PV)
-
Pregnancy and venous thromboembolism: ‘TIPPS’ for risk stratification
-
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation
-
Pregnancy and venous thromboembolism: ‘TIPPS’ for risk stratification